ESTUDIO MULTICÉNTRICO, DE EXTENSIÓN ABIERTO Y DE SEGURIDAD, PARA DESCRIBIR LA EXPERIENCIA CLÍNICA A LARGO PLAZO CON MEPOLIZUMAB EN PACIENTES CON SÍNDROME HIPEREOSINOFÍLICO (HES) PROCEDENTES DEL ESTUDIO 200622.

Article. 10.1016/j.thromres.2018.12.027. 2019

Biallelic TET2 mutation sensitizes to 5'-azacitidine in acute myeloid leukemia.

Stölzel F; (...); Allan, James M.

Article. 10.1172/jci.insight.150368. 2022

Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022

Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Platzbecker, Uwe; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2022-160127. 2022

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2022-158030. 2022

Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in HematologY Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools.

Cerisoli, Francesco; (...); Hernandez Rivas, Jesus Maria

Article. 10.1016/j.jval.2022.04.1729. 2022

Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.

Madry, Krzysztof; (...); Smith, Alex

Article. 10.1111/bjh.18542. 2022

Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.

Balaguer-Rosello, Aitana; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2020.12.019. 2021

Circulating megakaryocyte in primary myelofibrosis. An uncommon finding in a myelofibrosis blood smear.

Cantó PA, Peris MLS, Castera EM

Editorial Material. 10.5045/br.2021.2020269. 2021

Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia

Morote-Faubel, Mireya; (...); Cervera, Jose

Meeting Abstract. 10.1182/blood-2023-177571. 2023

Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.

Bersanelli M; (...); Della Porta MG

Article. 10.1200/JCO.20.01659. 2021

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).

Stahl M; (...); Zeidan AM

Article. 10.1016/j.blre.2023.101128. 2023

Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

Lopez Cadenas, Felix; (...); Diez-Campelo, Maria

Meeting Abstract. 10.1182/blood-2021-152678. 2021

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.

Tentori CA; (...); Della Porta MG

Article. 10.1200/JCO.23.02175. 2024

CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS

Calvete, O.; (...); Sole, F.

Meeting Abstract. 10.1016/j.leukres.2023.107176. 2023

Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

Gil-Manso, Rodrigo; (...); Alvarez-Larran, Alberto

Meeting Abstract. 10.1182/blood-2023-188875. 2023

CLINICAL APPLICATION OF THE MASSIVE SEQUENCING ADDRESSED IN ACUTE MYELOBLASTIC LEUKEMIA

Garcia, ML; (...); Gonzalez, EB

Meeting Abstract. 2017

Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Heuser, M; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.116. 2019

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (vol 100, pg 1181, 2021)

Heuser, Michael; (...); Cortes, Jorge E.

Article. 10.1007/s00277-021-04545-5. 2021

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.

Heuser M; (...); Cortes JE

Article. 10.1007/s00277-021-04465-4. 2021

Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Article. 10.1016/j.thromres.2021.07.009. 2021

Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre

Arnao, M; (...); Sanz, G

Meeting Abstract. 10.1016/j.clml.2019.09.254. 2019

Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group

Romero, Alejandra; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-163869. 2022

Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study

Pinana, JL; (...); Navarro, D

Article. 10.1093/cid/ciy792. 2019

Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)

Vicente, Navarro; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-190296. 2023

Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes

Riva, Elena; (...); Della Porta, Matteo G.

Meeting Abstract. 10.1182/blood-2022-166050. 2022

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.

Bernal, Teresa; (...); Montesinos, Pau

Article. 10.1002/cam4.6120. 2023

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Perl, AE; (...); Tiu, RV

Meeting Abstract. 2021

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.

Perl, Alexander E.; (...); Altman, Jessica K.

Article. 10.1038/s41408-022-00677-7. 2022

Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model

Nogueras, A; (...); Calleja, MA

Letter. 10.1136/ejhpharm-2019-001905. 2019

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Daver, Naval G.; (...); Kantarjian, Hagop M.

Meeting Abstract. 10.1182/blood-2019-128648. 2019

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Labrador, J; (...); GATLA Grp

Article. 10.1080/10428194.2018.1522438. 2019

Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics

Alonso, CM; (...); Barragan, E

Article. 10.1016/j.jmoldx.2018.09.009. 2019

CLINICAL-BIOLOGICAL AND PROGNOSTIC CHARACTERISTICS OF LOW RISK SMD WITHOUT RING SIDEROBLASTS AND COMPARISON WITH ITS COUNTERPART WITH RING SIDEROBLASTS

Cadenas Felix, Lopez; (...); Ferreiras David, Valcarcel

Meeting Abstract. 2021

Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study

Bassan, R; (...); Cong, Z

Article. 10.1007/s12325-019-00910-z. 2019

Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.

Pastor-Galán I; (...); Cervantes F

Article. 10.1016/j.medcli.2019.11.007. 2020

Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)

Colmenares, Rafael; (...); Montesinos, Pau

Meeting Abstract. 2023

Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes

Martinez-Losada, C; (...); Sanchez-Garcia, J

Letter. 10.3324/haematol.2018.188433. 2018

Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation

Stiff, PJ; (...); Sanz, G

Article. 10.1016/j.bbmt.2018.02.012. 2018

Collaborative model of home delivery program in haemophilia through an association of patients

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018

Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation.

Montoro J; (...); Piñana JL

Article. 10.1038/s41409-020-0943-0. 2020

COMPARISON OF AZACITIDINE AND DECITABINE FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS

Saiz-Rodriguez, M.; (...); Labrador, J.

Meeting Abstract. 2020

COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)

Kuendgen, A.; (...); Sanz, G.

Meeting Abstract. 2021

Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia

Ribera, JM; (...); PETHEMA Grp

Article. 10.1016/j.leukres.2018.03.010. 2018

Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo

Meeting Abstract. 2020

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Sargas, Claudia; (...); Montesinos, Pau

Article. 10.1038/s41408-023-00835-5. 2023

COMPARISON OF THREE PANELS OF NGS APPLICATION IN ONCOHEMATOLOGY TO DISCARD SOMATIC AND/OR GERMINAL VARIANTS

Guzman-Gimenez, C.; (...); Such, E.

Meeting Abstract. 2021

Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation

Solves, P; (...); Sanz, GF

Article. 10.1111/ejh.13270. 2019

Complex Karyotype with >= 3 Cytogenetic Alterations is a New Marker of Worse Prognosis in Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Genesca, Eulalia; (...); Maria Ribera, Josep

Meeting Abstract. 2020

Comprehensive detection of CRLF2 alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach.

Gil, Jose Vicente; (...); Barragan, Eva

Article. 10.3389/fmolb.2024.1362081. 2024

CONCORDANCE STUDY ON THE CATEGORIZATION OF NON-CANONICAL VARIANTS OF JAK2 GENE

Guzman-Gimenez, C.; (...); Such, E.

Meeting Abstract. 2021

Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes.

Zeidan, Amer M.; (...); Fenaux, Pierre

Article. 10.1182/blood.2022018604. 2023

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023

Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).

Aakash, Fnu; (...); Loghavi, Sanam

Article. 10.1016/j.modpat.2024.100615. 2024

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Gonzalez-Gil C; (...); Genesca E

Article. 10.3324/haematol.2024.285416. 2024

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Boluda, Blanca; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-160136. 2022

CO-OCCURRENCE PROFILES OF GERMLINE AND ACQUIRED VARIANTS IN MYELODYSPLASTIC SYNDROMES IN YOUNG ADULTS WITHOUT PRIOR ORGAN DYSFUNCTION

Hua, Chen-Liang Tzu; (...); Andres, Jerez

Meeting Abstract. 2021

Core Set of Patient-Reported Outcomes for Myelodysplastic Syndromes - EUMDS Delphi Study in Patients and Hematologists.

Stojkov, Igor; (...); Stauder, Reinhard

Article. 10.1182/bloodadvances.2021004568. 2021

Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups

Article. 10.1007/s00277-018-3277-x. 2018

Correction to: Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.

Montesinos P; (...); Sanz MÁ

Correction. 10.1007/s00277-020-03933-7. 2020

Corrigendum to "Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study" [Leuk. Res. 92 (March) (2020) 106352].

Rodríguez-Medina C; (...); Montesinos P

Correction. 10.1016/j.leukres.2020.106388. 2020

Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia (vol 13, 1302993, 2023)

Orgueira, Adrian Mosquera; (...); Encinas, Manuel Mateo Perez

Correction. 10.3389/fonc.2023.1302993. 2023

COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Gironella, M.; (...); Oyaguez, I

Meeting Abstract. 2019

COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN

Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.

Meeting Abstract. 2024

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

Mareque, M; (...); Sierra, J

Article. 10.2147/CEOR.S302097. 2021

Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.

Poveda JL; (...); Torres C

Article. 10.1080/14737167.2019.1635014. 2020

COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

Trillo, JL; (...); Torres, C

Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018

COST-EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN IN COMBINATION WITH STANDARD CHEMOTHERAPY IN FIRST-LINE TREATMENT IN PATIENTS WITH CD-33-POSITIVE ACUTE MYELOID LEUKEMIA IN SPAIN

Montesinos, P.; (...); Guinea, J. M.

Meeting Abstract. 2020

Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain

Arenaza, A; (...); Vinent, JL

Article. 10.2147/CEOR.S222879. 2019

COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN

Bonanad, S; (...); Gonzalez-Dominguez, A

Meeting Abstract. 2020

Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Lancet, Jeffrey; (...); Carraway, Hetty E.

Meeting Abstract. 10.1182/blood-2023-173149. 2023

COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330)

Rosenberg, Aaron; (...); Khouri, Jack

Meeting Abstract. 2023

Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis

Letter. 10.1111/hae.13733. 2019

Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Eduardo Megias, Juan; (...); Iorio, Alfonso

Meeting Abstract. 10.1182/blood-2019-127946. 2019

Cryopreservation of Allogeneic Hematopoietic Progenitor Cells in The Current SARS-Cov-2 Pandemic: Experience of A Single Centre

Moreno, D; (...); Carpio, N

Meeting Abstract. 2021

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).

Bewersdorf, Jan Philipp; (...); Zeidan, Amer M.

Article. 10.1016/j.blre.2023.101072. 2023

Current management of patients with chronic myelomonocytic leukemia

Mora, E, Sanz, GF

Review. 10.1097/CCO.0000000000000486. 2018

Current Results on Overall Survival with oral Azacitidine Therapy in Patients with acute Myeloid Leukemia in first Remission after intensive Chemotherapy in the Phase 3 QUAZAR Study

Pfeilstoecker, M.; (...); Roboz, G. J.

Meeting Abstract. 2022

CURRENT STATE OF ACUTE MYELOID LEUKEMIA IN SPAIN: RESULTS FROM A DELPHI STUDY ON EPIDEMIOLOGY, DISEASE MANAGEMENT AND UNMET NEEDS

Montesinos, P; (...); Sierra, J

Meeting Abstract. 2018

Current status of acute myeloid leukaemia in Spain: Results from a Delphi study on its epidemiology, disease management and unmet clinical needs.

Montesinos P, Gil A, Sierra J

Letter. 10.1016/j.medcli.2020.04.032. 2020

Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.

Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL

Editorial Material. 10.1016/j.farma.2024.08.001. 2024

Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.

Diaz-Gonzalez, Alvaro; (...); Such, Esperanza

Article. 10.3390/cancers15113039. 2023

Challenges in the diagnosis and treatment of secondary acute myeloid leukemia

Ossenkoppele, G, Montesinos, P

Review. 10.1016/j.critrevonc.2019.03.003. 2019

Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib plus azacitidine or placebo plus azacitidine.

Schuh, Andre C.; (...); Montesinos, Pau

Meeting Abstract. 2022

Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants.

Cicconi, L; (...); Abla, O

Article. 10.1038/s41408-021-00561-w. 2021

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols.

Sobas M; (...); PETHEMA, HOVON, PALG, GATLA cooperative groups

Article. 10.1111/ejh.13346. 2020

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Genesca, E; (...); Ribera, JM

Meeting Abstract. 10.1182/blood-2018-99-114559. 2018

Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide - an International Collaborative Study

Kayser, S; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-111768. 2018

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Kayser, Sabine; (...); Schlenk, Richard F.

Meeting Abstract. 10.1182/blood-2021-150281. 2021

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.

Kayser, Sabine; (...); Schlenk, Richard F.

Meeting Abstract. 10.3324/haematol.2022.281137. 2022

Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.

Kayser S; (...); Levis MJ

Article. 10.3324/haematol.2021.278645. 2022

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.

Martinez-Cuadron, David; (...); On Behalf Of The Pethema Group

Article. 10.3390/cancers14112817. 2022

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

Palanques-Pastor, Tomas; (...); Montesinos, Pau

Article. 10.1080/10428194.2021.1948031. 2021

Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort

Stahl, M; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-112974. 2018

CHARACTERIZATION OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA BY MEANS OF IMMUNOLOGICAL AND MOLECULAR TECHNIQUES: RESULTS OF THE GEPTT NATIONAL COLLECTION

Liquori, A.; (...); Gomez-Segui, I

Meeting Abstract. 2019

CHARACTERIZATION OF CHARACTERISTIC MORPHOLOGICAL ALTERATIONS IN PATIENTS WITH MDS/CMML AND GENE MUTATIONS OF SPLICING DIFFERENT TO SF3B1

Marco Ayala, J.; (...); Sanz, G.

Meeting Abstract. 2019

CHARACTERIZATION OF THE GENOMIC AND TRANSCRIPTOMIC PROFILE OF THE ACUTE MYELOID LEUKEMIA (AML) SUBGROUP "CHROMATIN-SPLICEOSOME"

Alessandro, Liquori; (...); Zamora Jose, Cervera

Meeting Abstract. 2020

Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.

Ribera JM; (...); Orfao A

Article. 10.1182/blood.2020007311. 2020

Chromosomal Abnormalities and Prognosis in NPM1 -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt, L; (...); Schliemann, C

Article. 10.1200/JCO.19.00416. 2019

Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.

Caballero JC; (...); Díez Campelo M

Article. 10.1007/s00277-019-03751-6. 2019

Chronic Myelomonocytic Leukemia ( CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Castano-Diez, Panelsandra; (...); Diaz-Beya, Marina

Meeting Abstract. 10.1182/blood-2023-173311. 2023

Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)

Gonzalez, Carmen; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2023-180646. 2023

Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.

Komrokji RS; (...); Della Porta MG

Article. 10.1016/S2352-3026(24)00251-5. 2024

Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

Review. 10.1080/17512433.2019.1573668. 2019

Decitabine as Salvage Therapy after Azacitidine in AML

De La Fuente, A; (...); Montesinos, P

Meeting Abstract. 2019

Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial.

Montesinos, Pau, Sossa-Melo, Claudia

Article. 10.1016/S2352-3026(23)00308-3. 2023

Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project

Blade, J; (...); Lizan, L

Article. 10.1136/bmjopen-2017-018850. 2018

Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021

Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.

Stojkov I; (...); Siebert U

Article. 10.1182/bloodadvances.2022008360. 2023

Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Alvarez-Roman, MT; (...); Badia, X

Article. 10.1177/2284240319880534. 2019

DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Alvarez, E.; (...); Badia, F. J.

Meeting Abstract. 2019

Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024

Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024

DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

Poveda, J. L.; (...); Vitoria, I

Meeting Abstract. 2019

Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain

Badia, X; (...); Poved, JL

Article. 10.1080/21678707.2019.1652163. 2019

Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.

Rochau U; (...); Stauder R

Article. 10.1111/bjh.16654. 2020

Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia

Megias-Vericat, JE; (...); Spanish PETHEMA Grp

Article. 10.4084/MJHID.2019.016. 2019

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.

Montesinos P; (...); DiNardo CD

Article. 10.1182/bloodadvances.2023011914. 2024

Differentiation Syndrome with Lower-intensity Treatments for Acute Myeloid Leukemia.

Fathi, Amir T; (...); de Botton, Stephane

Review. 10.1002/ajh.26142. 2021

Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)

Santini, Valeria; (...); Zeidan, Amer M.

Meeting Abstract. 10.1182/blood-2022-160282. 2022

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Sanz GF, Ibañez M, Such E

Article. 10.1182/bloodadvances.2019000680. 2019

Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

Suárez EU; (...); Montesinos P

Article. 10.1007/s00277-024-05840-7. 2024

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

Azibeiro Melchor, Raul; (...); Ossenkoppele, Gert J.

Meeting Abstract. 10.1182/blood-2021-150766. 2021

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Hutchings, Martin; (...); Subklewe, Marion

Meeting Abstract. 10.1182/blood-2023-173302. 2023

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/17512433.2023.2174523. 2023

Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia

Review. 10.1007/s00277-020-04186-0. 2020

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Pfeilstocker, Michael; (...); Greenberg, Peter L.

Meeting Abstract. 10.1182/blood-2022-158671. 2022

Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

Ribera, E; (...); Hernandez-Novoa, B

Article. 10.1016/j.eimc.2016.11.015. 2018

Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.

Torres Martínez E; (...); Vento M

Article. 10.1016/j.anpedi.2020.03.009. 2020

Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).

Dinardo, CD; (...); Dohner, H

Meeting Abstract. 2020

Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (RR) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.

Levis, MJ; (...); Bahceci, E

Meeting Abstract. 2019

EFFECT OF MISSENSE MUTATIONS IN THE SPLICING OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA

Morote-Faubel, M.; (...); Cervera, J.

Meeting Abstract. 2019

Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

De Botton, Stephane; (...); Fenaux, Pierre

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7006. 2021

EFFECTIVENESS AND SAFETY OF THE INFUSION OF DONOR LYMPHOCYTES AFTER HAPLOIDENTICAL TRANSPLANTATION OF HEMATOPOYETIC PROGENITOR CELLS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: MULTICENTRIC RETROSPECTIVE STUDY OF THE HEMATOPETIC SPANISH TRIPASHOLE GROUP

Martin-Sanchez, Guillermo; (...); Bermudez, Aranzazu

Meeting Abstract. 2020

EFFECTIVENESS AND TOXICITY OF THE USE OF INOTUZUMAB (INO) IN PATIENTS WITH RESISTANT OR RECALLING (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (LAL). STUDY OF PATIENTS INCLUDED IN INO'S EXPANDED USE PROGRAM

Ribera Santasusana, J. M.; (...); Valero, M.

Meeting Abstract. 2021

Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021

Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Pleyer, Lisa; (...); Greil, Richard

Meeting Abstract. 10.1182/blood-2019-123941. 2019

Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia

Ribera, JM; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2017.1397661. 2018

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 10.1182/blood-2018-99-110439. 2018

Efficacy and Safety of Single-Agent Quizartinib (Q), Potent and SeleEfficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 2019

Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) - Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Jonas, BA; (...); Levis, MJ

Meeting Abstract. 10.1016/j.clml.2019.07.097. 2019

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Perez-Lamas, Lucia; (...); Garcia Gutierrez, Valentin

Meeting Abstract. 10.1182/blood-2023-184989. 2023

eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Megias-Vericat, JE

Meeting Abstract. 2018

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/14728214.2021.2009800. 2022

Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial.

Smith CC; (...); Bahceci E

Article. 10.1182/blood-2019-122620. 2019

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

DiNardo CD; (...); Döhner H

Article. 10.1016/S1470-2045(21)00494-0. 2021

Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.

de Botton, Stephane; (...); DiNardo, Courtney D.

Article. 10.1182/blood.2021014901. 2022

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Montesinos, Pau; (...); Recher, Christian

Meeting Abstract. 10.1182/blood-2024-194356. 2024

Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine

Diaz-Gonzalez, Alvaro; (...); Such, Esperanza

Meeting Abstract. 10.1182/blood-2023-180691. 2023

Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)

Segui, Ines Gomez; (...); Garma, Julio Del Rio

Meeting Abstract. 2024

Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.

Dohner, H; (...); Roboz, GJ

Meeting Abstract. 2020

EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

Badia, F. J.; (...); Shepherd, J.

Meeting Abstract. 2019

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Lopez Cadenas, Felix; (...); Diez-Campelo, Maria

Meeting Abstract. 10.1182/blood-2022-168718. 2022

EVALUATION OF THE EFFICACY AND SAFETY OF NILOTINIB 300 BID IN SECOND LINE AFTER IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA

Garcia Gutierrez, V; (...); Steegmann, J. L.

Meeting Abstract. 2019

Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

Mosquera Orgueira, Adrian; (...); Perez Encinas, Manuel Mateo

Article. 10.3389/fonc.2022.968340. 2022

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Labrador, Jorge; (...); Manuel Alonso-Dominguez, Juan

Meeting Abstract. 10.1182/blood-2022-163016. 2022

Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.

Labrador, Jorge; (...); Montesinos, Pau

Article. 10.1002/cncr.35431. 2024

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

Boluda B; (...); Montesinos P

Article. 10.1080/10428194.2021.1938031. 2021

Evolving treatment patterns and outcomes in older patients (=60 years) with AML: changing everything to change nothing?

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1038/s41375-020-01058-4. 2020

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Pemmaraju, Naveen; (...); Daver, Naval

Meeting Abstract. 10.1182/blood-2021-146666. 2021

Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases

del Pozo, Victoria; (...); Rua-Figueroa, Inigo

Review. 10.3389/fimmu.2023.1310211. 2024

Exploratory analysis for the implementation of antineoplastic logarithmic dose banding

Albert-Mari, A; (...); Poveda-Andres, JL

Article. 10.1007/s11096-018-0714-9. 2018

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Mosquera Orgueira, Adrian; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-180710. 2023

EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY

F, de Andres-Nogales; (...); Martinez, M.

Meeting Abstract. 2019

Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.1002/jca.21901. 2021

Factors Associated With Survival in Secondary Acute Myeloid Leukemia in Colombia

Sossa, Claudia; (...); Marcela Cuervo, Diana

Meeting Abstract. 2023

Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation

Solves P; (...); Carpio N

Article. 10.1007/s00277-017-3168-6. 2018

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

Ribera JM; (...); Sancho JM

Article. 10.3324/haematol.2023.283342. 2024

Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease

Beltran, B; (...); Nos, P

Article. 10.1159/000492626. 2019

Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021

FINAL RESULTS OF THE LAL-RI 08 PROTOCOL FOR ADOLESCENTS AND YOUNG ADULTS (AAJ) WITH LYMPHOBLASTIC ACUTE LEUKEMIA (LAL) OF STANDARD RISK (RE)

Santasusana, JMR; (...); Vale, AODCE

Meeting Abstract. 2018

Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.

Zeidan, Amer M.; (...); Santini, Valeria

Article. 10.1038/s41375-022-01724-9. 2022

First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).

Jabbour, Elias; (...); Ribera, Josep-Maria

Meeting Abstract. 2023

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Jabbour, Elias; (...); Ribera, Jose-Maria

Meeting Abstract. 2023

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

Salamero, Olga; (...); Somervaille TCP

Article. 10.1200/JCO.19.03250. 2020

FITNESS ASSESSMENT IN ACUTE MYELOID LEUKEMIA: RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF EUROPEAN LEUKEMIA NET.

Venditti, Adriano; (...); Ossenkoppele, Gert J

Article. 10.1182/bloodadvances.2024013744. 2025

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

Pallarès V; (...); Casanova, I

Article. 10.3390/cancers10110436. 2018

Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7013. 2021

Follow-up of Patients With FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukaemia in the Phase 3 ADMIRAL Trial

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 2022

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

Perl AE; (...); Levis MJ

Article. 10.1182/blood.2021011583. 2022

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia

Genesca, E; (...); Ribera, JM

Article. 10.1186/s13045-018-0639-8. 2018

Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia

Motllo C; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2017.1326596. 2018

Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain.

Ribera, Josep-Maria; (...); Pinana, Jose-Luis

Article. 10.1016/j.clml.2021.06.024. 2021

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Cortes, JE; (...); Baer, MR

Meeting Abstract. 10.1182/blood-2018-99-114126. 2018

FUNCTIONAL CLASSIFICATION OF DEEP INTRONIC VARIANTS IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA

Liquori, A.; (...); Cervera Zamora, J.

Meeting Abstract. 2019

FUNCTIONAL RECLASSIFICATION THROUGH MINIGENE TESTS OF MISSENSE VARIANTS WITH EFFECT ON SPLICING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Morote-Faubel, Mireya; (...); Cervera, Jose

Meeting Abstract. 2020

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial

Ravandi, Farhad; (...); Dombret, Herve

Meeting Abstract. 2020

Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial

Pfeilstocker, M.; (...); Dombret, H.

Meeting Abstract. 2021

Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.

Mosquera Orgueira A; (...); Bello López JL

Article. 10.1371/journal.pone.0247093. 2021

Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology

D'Amico, Saverio; (...); Della Porta, Matteo Giovanni

Meeting Abstract. 10.1182/blood-2024-209541. 2024

GENES BELONGING TO THE SWI/SNF CHROMATIN REMODELING COMPLEXES ARE MUTATED AT HIGH FREQUENCY IN RARE T(11;17)(Q23;Q21)/ZBTB16-RARA ACUTE MYELOID LEUKEMIA PATIENTS

Fabiani, E.; (...); Voso, M. T.

Meeting Abstract. 2020

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.

Plaza J; (...); Moret-Tatay I

Article. 10.3390/ijms25073717. 2024

GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES

Bernard, E.; (...); Papaemmanuil, E.

Meeting Abstract. 10.1016/j.leukres.2023.107146. 2023

Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea.

Alvarez-Larrán A; (...); Hernández-Boluda JC

Letter. 10.1038/s41375-020-0849-2. 2020

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Gonzalez-Gil, Celia; (...); Genesca, Eulalia

Article. 10.3324/haematol.2022.281196. 2023

GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS

Santiago, M.; (...); Cervera-Zamora, J.

Meeting Abstract. 10.1016/j.leukres.2023.107247. 2023

GETH-CLL4: Long-term follow-up of a pilot trial evaluating the addition of ofatumumab to the conditioning regimen of patients with chronic lymphocytic leukemia undergoing allogeneic HCT

Montesinos, Pau; (...); Delgado, Julio

Meeting Abstract. 2018

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML.

Perl AE; (...); Levis MJ

Article. 10.1056/NEJMoa1902688. 2019

Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukaemia who have common AML comutations or a high FLT3-internal tandem duplication allelic ratio

Levis, MJ; (...); Bahceci, E

Meeting Abstract. 2020

Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial

Perl, AE; (...); Levis, MJ

Meeting Abstract. 10.1158/1538-7445.AM2019-CT184. 2019

GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL

Perl, A. E.; (...); Levis, M. J.

Meeting Abstract. 2019

Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial

Perl, A. E.; (...); Levis, M. J.

Meeting Abstract. 2019

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

Ballesta-López O; (...); Montesinos P

Review. 10.2217/fon-2020-0700. 2020

Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.

Heuser, M; (...); Cortes, JE

Meeting Abstract. 2020

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.

Sekeres MA; (...); Cortes JE

Article. 10.1038/s41375-023-02001-z. 2023

Glasdegib plus low-dose cytarabine in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): BRIGHT AML 1003 final report and 4-year overall survival follow-up

Heuser, M; (...); Cortes, JE

Meeting Abstract. 2020

Glasdegib Plus Low-Dose Cytarabine in Acute Myeloid Leukemia or Myelodysplastic Syndrome: BRIGHT AML 1003 Final Report and 4-Year Overall Survival Follow-Up

Heuser, Michael; (...); Cortes, Jorge E.

Meeting Abstract. 2020

Glasdegib with LDAC in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Unsuitable for Intensive Chemotherapy: Effects on Transfusions and Marrow Recovery vs LDAC Alone

Wang, ES; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.114. 2019

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial.

Roboz GJ; (...); Döhner H

Article. 10.1182/bloodadvances.2023012062. 2024

Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022

Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12568. 2017

Haploidentical non-manipulated stem cell transplant in patients with non-hodgkin lymphoma: Spanish experience

Dorado, N; (...); Diez-Martin, JL

Meeting Abstract. 2019

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Sobas, Marta; (...); Maria Hernandez-Rivas, Jesus

Meeting Abstract. 10.1182/blood-2021-149521. 2021

Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study

Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units

Article. 10.7399/fh.10935. 2018

Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022

Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.

Solana-Altabella A; (...); Montesinos P

Article. 10.1111/ejh.13604. 2021

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

DiNardo, Courtney D.; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2021-147601. 2021

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).

Dinardo, Courtney Denton; (...); De Botton, Stephane

Meeting Abstract. 2022

Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.

Dohner, Hartmut; (...); De Botton, Stephane

Meeting Abstract. 2022

Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT.

Ruggeri A; (...); Nagler A

Article. 10.1038/s41409-019-0582-5. 2019

High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022

Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022

Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021

How can artificial intelligence optimize value-based contracting?

Poveda, Jose Luis; (...); Medrano, Ignacio H.

Letter. 10.1186/s40545-022-00475-3. 2022

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M; (...); Zeidan AM

Article. 10.1182/bloodadvances.2018016121. 2018

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Salamero, Olga; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2021-152183. 2021

Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.

Salamero, Olga; (...); Montesinos, Pau

Article. 10.1016/S2352-3026(24)00132-7. 2024

Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial.

Konopleva, Marina Y.; (...); Wei, Andrew H.

Article. 10.1182/bloodadvances.2021006303. 2022

Identification of Leukemia-Associated Immunophenotypes by Databaseguided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia

Pinero, Paula; (...); Tarin, Fabian

Article. 10.3390/cancers14164010. 2022

Identification of patient-reported outcomes measures (PROMs) and patient-reported experiences measures (PREMs) in Gaucher disease in Spain.

Giraldo P; (...); Morales-Conejo M

Article. 10.1016/j.medcli.2024.06.006. 2024

Identifying prognostic gene panels in acute myeloid leukemia.

Sanchez-Garcia, Joaquin; (...); Montesinos, Pau

Article. 10.1080/17474086.2023.2193322. 2023

IDH1-mutated relapsed or refractory AML: current challenges and future prospects

Review. 10.2147/BLCTT.S177913. 2019

Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.

Cordón L; (...); Sanz J

Article. 10.1007/s00277-024-05758-0. 2024

Immune Reconstitution Profiling Suggests Antiviral Protection After Transplantation with Omidubicel: a Phase 3 Substudy.

Szabolcs, Paul; (...); Horwitz, Mitchell E.

Article. 10.1016/j.jtct.2023.04.018. 2023

IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)

Ibanez, Mariam; (...); Sanz, Guillermo

Meeting Abstract. 2020

Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 2023

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 10.1182/blood-2022-169011. 2022

IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO FLT3 INHIBITION WITH QUIZARTINIB IN AML WITH FLT3-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 2023

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.

Barba P; (...); Ribera JM

Article. 10.1097/HS9.0000000000000810. 2023

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Article. 10.1080/10428194.2020.1839650. 2020

IMPACT OF CYTOGENETIC ABNORMALITIES DEFINING AML MYELODYSPLASIA-RELATED (WHO AND ICC 2022) IN FIRST LINE DECITABINE IN UNFIT AML PATIENTS

de la Fuente, Adolfo; (...); Tormo, Mar

Meeting Abstract. 2023

Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.

Ayala, Rosa; (...); Montesinos, Pau

Article. 10.3390/cancers14235799. 2022

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Matteuzzi, Tommaso; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2021-152215. 2021

Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort

Stahl, M; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-112495. 2018

Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.

Paiva B; (...); PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) coop

Article. 10.1038/s41375-021-01126-3. 2021

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.

de Swart L; (...); EUMDS Registry Participants

Article. 10.3324/haematol.2018.212217. 2020

Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Pastor-Galan, Irene; (...); Hernandez-Boluda, Juan Carlos

Article. 10.1038/s41375-024-02389-2. 2024

Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Badia X; (...); Hernández C

Article. 10.1186/s13023-020-01507-4. 2020

IMPACT OF THE TREATMENT OF THE PURE APLASIA OF THE RED SERIES; EXPERIENCE IN A CENTER

Marco, Ayala Javier; (...); Solves, Alcaina Pilar

Meeting Abstract. 2020

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.

Hoeks M; (...); EUMDS Registry Participants

Article. 10.3324/haematol.2018.212332. 2020

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.

Kayser, Sabine; (...); Schlenk, Richard F.

Article. 10.3324/haematol.2022.282127. 2023

Impact of voriconazole plasma concentrations on treatment response in critically ill patients

Ruiz, J; (...); Ramirez, P

Article. 10.1111/jcpt.12817. 2019

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Marconi, Giovanni; (...); Martinelli, Giovanni

Meeting Abstract. 10.1182/blood-2023-184745. 2023

Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases

Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL

Article. 10.7399/fh.11262. 2020

IMPLEMENTATION OF MASSIVE SEQUENCING TECHNOLOGIES TO THE DETECTION OF MUTATIONS IN THE ABL KINASE DOMAIN OF BCR-ABL REORDERING

Simarro, CS; (...); Gonzalez, EB

Meeting Abstract. 2017

Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1159/000478969. 2018

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)

Bernard, Elsa; (...); Elias, Harold K

Article. 10.1038/s41591-021-01367-w. 2021

Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Bernard, E; (...); Papaemmanuil, E

Article. 10.1038/s41591-020-1008-z. 2020

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.

Onecha E; (...); Ayala R

Article. 10.1111/bjh.16432. 2020

In MDS, is higher risk higher reward?

Sanz GF

Article. 10.1182/hematology.2019000042. 2019

IN VIVO MODELS TO STUDY THE COOPERATION BETWEEN SPLICING AND DNA METHYLATION IN MYELODYSPLASTIC SYNDROMES

Martinez-Valiente, Cristina; (...); Sanjuan-Pla, Alejandra

Meeting Abstract. 2020

Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group

Ribera, Josep-Maria; (...); Feliu, Evarist

Article. 10.1002/cncr.32156. 2019

Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.

Rodríguez-Veiga R; (...); Sanz GF

Article. 10.1007/s00277-019-03744-5. 2019

Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.

Castillo MI; (...); Díaz TM

Article. 10.1002/cam4.6300. 2023

Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.3390/cancers15082267. 2023

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Sirenko, Maria; (...); Papaemmanuil, Elli

Meeting Abstract. 10.1182/blood-2022-162397. 2022

Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients

Pinana, JL; (...); Navarro, D

Article. 10.1111/tid.13158. 2019

Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.

Sobas, Marta; (...); Montesinos, Pau

Article. 10.1007/s00277-023-05582-y. 2023

Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials

Barba, P; (...); Ribera, JM

Article. 10.1111/ejh.13178. 2019

In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph plus ALL.

Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.6533. 2024

In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph plus ALL

Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria

Meeting Abstract. 10.1016/S2152-2650(24)00426-9. 2024

Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Vericat, JEM; (...); Bonanad, S

Meeting Abstract. 2018

Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Labrador, Jorge; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-162591. 2022

INFECTIOUS EVENTS DURING TREATMENT WITH HYPOMETHYLATING AGENTS WORSE THE PROGNOSIS AND QUALITY OF LIFE OF PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOBLASTIC LEUKEMIA (LAM), A STUDY OF THE GESM

Vilorio-Marques, Laura; (...); Bernal, Teresa

Meeting Abstract. 2020

Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy

Bastida, G; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2017.1323267. 2017

Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.

Ruiz J; (...); Poveda JL

Article. 10.23736/S0026-4946.18.04978-2. 2018

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Article. 10.1097/FPC.0000000000000431. 2021

INHIBITORS OF THE MUTATED DEHYDROGENASE (MIDH), IVOSIDENIB OR ENASIDENIB, IN COMBINATION WITH AZACITINE (AZA) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

Montesinos, P; (...); Vyas, P

Meeting Abstract. 2018

IN-SILICO AND IN VITRO STUDY OF MUTATIONS THAT ALTER THE SPLICING PROCESS IN PATIENTS WITH MYELODISPLASIC SYNDROMES

Boluda-Navarro, M.; (...); Cervera, J.

Meeting Abstract. 2019

Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.

Simoes C; (...); Paiva B

Article. 10.1182/bloodadvances.2022008141. 2023

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

Mosquera-Orgueira, Adrian; (...); Hernandez-Boluda, Juan C.

Letter. 10.1002/hem3.60. 2024

INTENSIVE CHEMOTHERAPY VERSUS DECITABINE FIRST LINE LAM OVER 60 YEARS OLD

De la Fuente, A.; (...); Montesinos, P.

Meeting Abstract. 2019

Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12842. 2019

Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.

Solana-Altabella A; (...); Poveda JL

Article. 10.1177/1078155220904410. 2020

Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen

Montoro, J; (...); Pinana, JL

Article. 10.1111/ejh.13202. 2019

INVASIVE FUNGAL INFECTION IN ADULT PATIENTS SUBMITTED TO UMBILICAL CORD BLOOD TRANSPLANTATION

Montoro, J.; (...); Pinana, J. L.

Meeting Abstract. 2018

Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP

Article. 10.1136/ejhpharm-2020-002322. 2020

Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

Pozo-Rosich P; (...); Irimia P

Article. 10.1186/s10194-024-01747-w. 2024

Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.

Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula

Article. 10.3390/antibiotics13080706. 2024

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

Montesinos, Pau; (...); Dohner, Hartmut

Article. 10.1056/NEJMoa2117344. 2022

Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.

Montesinos, Pau, de Botton, Stephane, Dohner, Hartmut

Letter. 10.1056/NEJMc2206489. 2022

Ivosidenib plus Azacitidine vs Placebo plus Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study

de Botton, Stephane; (...); Doehner, Hartmut

Meeting Abstract. 2023

Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First

Montesinos, Pau; (...); Dombret, Herve

Meeting Abstract. 10.1182/blood-2023-187286. 2023

ladademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

Salamero, Olga; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-168945. 2022

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors.

Cruz, David; (...); Gallardo, David

Article. 10.3389/fimmu.2023.1066393. 2023

Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.

Gomez, E; (...); Fernandez-Rodriguez, C M

Article. 10.1111/apt.18004. 2024

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

Martínez-Cuadrón D; (...); Sanz MA

Article. 10.1038/leu.2017.178. 2018

Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Rodriguez-Arboli, E; (...); GETH Grp Espanol Trasplante Hemato

Article. 10.1016/j.jtct.2020.12.029. 2021

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.

Recher, Christian; (...); Montesinos, Pau

Article. 10.1038/s41375-021-01425-9. 2022

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.

Wei, Andrew H.; (...); Roboz, Gail J.

Letter. 10.1002/ajh.26847. 2023

Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Papayannidis, C; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.111. 2019

Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.

Smith, BD; (...); Cortes, JE

Meeting Abstract. 2019

Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation

de Koning, Coco; (...); Nierkens, Stefan

Article. 10.1038/s41409-021-01417-4. 2021

LYMPHOPENIA IS HIGHLY PREVALENT IN MDS AND PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR IPSS-R VERY-LOW AND LOW-RISK PATIENTS. AN ANALYSIS FROM THE EU-MDS REGISTRY

Silzle, T.; (...); Smith, A.

Meeting Abstract. 2021

Lymphopenia is highly prevalent in MDS and provides prognostic information for IPSS-R (very)-low-risk patients. An analysis from the EU-MDS registry

Silzle, T.; (...); Smith, A.

Meeting Abstract. 2021

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Hernandez Sanchez, Alberto; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2022-167138. 2022

Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes.

Mosquera Orgueira, Adrian; (...); Valcarcel, David

Article. 10.1097/HS9.0000000000000961. 2023

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Mosquera Orgueira, Adrian; (...); Hernandez Boluda, Juan Carlos

Meeting Abstract. 10.1182/blood-2022-158669. 2022

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.

Mosquera-Orgueira A; (...); Hernández-Boluda JC

Article. 10.1097/HS9.0000000000000818. 2023

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Hernandez Sanchez, Alberto; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2023-183029. 2023

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Zeidner, Joshua F; (...); Vyas, Paresh

Article. 10.1182/blood.2024027408. 2025

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

Sanz, MA; (...); Lo-Coco, F

Article. 10.1182/blood-2019-01-894980. 2019

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.

Onida F; (...); Pleyer L

Article. 10.1182/blood.2023023476. 2024

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Ravandi, F; (...); Dombret, H

Article. 10.1186/s13045-021-01142-x. 2021

Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.

Stahl M; (...); Zeidan AM

Article. 10.1038/s41375-020-0783-3. 2020

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

Bowen, David; (...); de Witte, Theo M.

Meeting Abstract. 10.1182/blood-2021-150322. 2021

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Smoljanovic, Inga Mandac; (...); Bowen, David

Meeting Abstract. 10.1182/blood-2022-167716. 2022

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

Buske C; (...); Passamonti F

Article. 10.1016/j.esmoop.2022.100403. 2022

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022

MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA

Sargas Simarro, C.; (...); Barragan Gonzalez, E.

Meeting Abstract. 2019

Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.

Simoes C; (...); Montesinos P

Article. 10.1182/bloodadvances.2020003195. 2021

Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022

Metyrapone as treatment in the neonatal McCune-Albright syndrome

de Mingo, Carmen; (...); Garcia-Robles, Ana

Article. 10.1515/jpem-2020-0036. 2020

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial

Sierra, Jorge; (...); Venditti, Adriano

Article. 10.1182/bloodadvances.2023009847. 2023

Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones

Alfonso Pierola, Ana; (...); Prosper, Felipe

Meeting Abstract. 10.1182/blood-2023-188865. 2023

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine +/- idasanutlin in relapsed or refractory acute myeloid leukemia

Montesinos, P; (...); Fenaux, P

Article. 10.2217/fon-2020-0044. 2020

MIRROS: An ongoing randomized phase 3 trial of idasanutlin plus ARA-C in patients with relapsed or refractory acute myeloid leukemia.

Montesinos, P; (...); Fenaux, P

Meeting Abstract. 2019

MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL

Gonzalez-Romero, E.; (...); Cervera-Zamora, J.

Meeting Abstract. 2021

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.

Sirenko, Maria; (...); Papaemmanuil, Elli

Article. 10.1182/blood.2023023723. 2024

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH(1) Acute Myeloid Leukemia

De Botton, Stephane; (...); Fenaux, Pierre

Meeting Abstract. 10.1182/blood-2021-144912. 2021

MOLECULAR CHARACTERIZATION OF ACUTE LEUKAEMIA OF CHILD, ADOLESCENT AND YOUNG ADULT THROUGH MASSIVE GUIDED SEQUENCING

Llop Garcia, M.; (...); Barragan Gonzalez, E.

Meeting Abstract. 2019

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo plus AZA in the AGILE Study

Doehner, Hartmut; (...); De Botton, Stephane

Meeting Abstract. 10.1182/blood-2022-159473. 2022

Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.

De Botton, Stephane; (...); Dohner, Hartmut

Meeting Abstract. 2022

MOLECULAR CHARACTERIZATION OF VARIANTS THAT ALTER SPLICING (VAS) IN PATIENTS WITH MYELODYSPLASIC SYNDROMES

Boluda-Navarro, M.; (...); Cervera, J.

Meeting Abstract. 2020

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.

Sargas, Claudia; (...); On Behalf Of Pethema Group

Article. 10.3390/cancers15020438. 2023

Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Ribera J; (...); Ribera JM

Article. 10.1002/gcc.22788. 2019

Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications

Bernard, Elsa; (...); Papaemmanuil, Elli

Meeting Abstract. 10.1182/blood-2023-186863. 2023

Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications.

Bernard, Elsa; (...); Papaemmanuil, Elli

Article. 10.1182/blood.2023023727. 2024

Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021

Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021

MONITORING MINIMUM RESIDUAL DISEASE (EMR) THROUGH NGS CONFIRMS PROGNOSTIC VALUE

De La Fuente, EO; (...); Diaz, RA

Meeting Abstract. 2018

Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.

Fernandez-Megia, MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.10793. 2018

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

Lin, Chenyu; (...); Horwitz, Mitchell E.

Article. 10.1016/j.jtct.2023.01.031. 2023

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3(mut+)) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Esteve, J; (...); Bahceci, E

Meeting Abstract. 10.1182/blood-2018-99-110976. 2018

Multicentre Implementation of Next Generation Sequencing to Acute Myeloid Leukemia Patients in PETHEMA Spanish Collaborative Group

Sargas, C; (...); Barragan, E

Meeting Abstract. 2019

Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021

Multiomics Characterization of Normal CD34+Hematopoietic Progenitor Cells (HPC) and Blasts in the Bone Marrow (BM) and Peripheral Blood (PB) of Patients with Acute Myeloid Leukemia (AML)

Simoes, Catia; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2023-185760. 2023

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).

Dinardo, CD; (...); Vyas, P

Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.7042. 2018

Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia

Fabiani E; (...); Voso MT

Article. 10.1002/cam4.3904. 2021

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

Martin, I; (...); Tormo, M

Article. 10.1111/bjh.17675. 2021

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Fenaux, P; (...); ESMO Guidelines Comm

Article. 10.1016/j.annonc.2020.11.002. 2021

NATIONAL EXPERIENCE WITH THE USE OF VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Labrador, J.; (...); Montesinos, P.

Meeting Abstract. 2020

National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022

Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.

Sargas C; (...); Montesinos P

Article. 10.3324/haematol.2020.263806. 2021

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

NEW MODEL TO QUANTIFY THE IN VITRO PHARMACOLOGICAL ACTIVITY OF BI-SPECIFIC ANTIBODIES IN HAEMATOLOGIC MALIGNANCIES

Primo, D.; (...); Ballesteros, J.

Meeting Abstract. 2017

NGS ANALYSIS IN ADULTS GREATER THAN 65 YEARS DIAGNOSED OF ACUTE MYELOID LEUKEMIA IN LOW INTENSITY TREATMENTS

Garcia, AB; (...); Lopez, JM

Meeting Abstract. 2017

Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/II Trial

Horwitz, ME; (...); Sanz, G

Meeting Abstract. 10.1016/j.bbmt.2017.12.628. 2018

No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Castano-Bonilla, Tamara; (...); Montesinos, Pau

Article. 10.1155/2022/3132941. 2022

Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation

Balaguer-Rosello, A; (...); Sanz, Jaime

Article. 10.1016/j.bbmt.2019.05.024. 2019

Non-infectious neurologic complications after allogeneic hematopoietic stem cell transplantation (ALLO-HSCT)

Balaguer Rosello, Aitana; (...); Sanz, Jaime

Meeting Abstract. 2019

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective.

De Witte T; (...); Smith A

Article. 10.3324/haematol.2020.266817. 2020

Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies studies and correlation with flt3 mutations and polyunsaturated fatty acid metabolism.

Mazzarella L; (...); Pelicci PG

Article. 10.3324/haematol.2019.223925. 2020

OBSERVATIONAL CLINICAL TRIAL FOR THE VALIDATION OF A TEST OF PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA

Montesinos, P.; (...); Sanz, M.

Meeting Abstract. 2017

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Cortes, Jorge E.; (...); Wei, Andrew H.

Meeting Abstract. 10.1182/blood-2021-144905. 2021

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.

de Botton, Stephane; (...); Cortes, Jorge

Article. 10.1182/bloodadvances.2022009411. 2023

Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Cortes, Jorge E.; (...); De Botton, Stephane

Meeting Abstract. 10.1182/blood-2022-167330. 2022

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Watts, Justin M.; (...); Cortes, Jorge E.

Meeting Abstract. 10.1182/blood-2019-123920. 2019

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

Watts, Justin M.; (...); Cortes, Jorge E.

Article. 10.1016/S2352-3026(22)00292-7. 2022

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial

Cortes, Jorge E.; (...); Olutasidenib Combination Therapy Study Grp

Article. 10.1186/s13045-024-01657-z. 2025

Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).

Cortes J; (...); Watts JM

Article. 10.1080/10428194.2024.2333451. 2024

Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.

Horwitz, ME; (...); Sanz, G

Article. 10.1182/blood.2021011719. 2021

Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Poveda, JL

Meeting Abstract. 2018

OPTIMIZATION OF THE EFFICIENCY OF GENETIC EDITING OF HEMAPOYETIC PROGENITOR CELLS USING CRISPR/CAS9 RIBONUCLEOPROTEINS

Martinez-Valiente, C.; (...); Sanjuan-Pla, A.

Meeting Abstract. 2019

OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT

Flores-Moreno, S.; (...); Gil, A.

Meeting Abstract. 2024

Oral Azacitidine (Oral-AZA) improves Overall Survival (OS) and Relapse-free Survival (RFS) for patients with Acute Myeloid Leukemia (AML) in first remission after Intensive Chemotherapy (IC), regardless of amount of consolidation received: Results of the QUAZAR AML-001 maintenance trial

Dohner, H.; (...); Ravandi, F.

Meeting Abstract. 2021

Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukaemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

Wei, Andrew; (...); Roboz, Gail

Meeting Abstract. 2022

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

Wei AH; (...); Roboz GJ

Article. 10.1056/NEJMoa2004444. 2020

Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.

Sobas M; (...); Giebel S

Article. 10.1016/j.clml.2019.09.616. 2020

Outcome of Acute Myeloid Leukemia with Inv(3)(Q21q26.2)/ T(3;3)(Q21;Q26.2). Experience of the Spanish PETHEMA and CETLAM Groups

Sitges, M; (...); CETLAM Cooperative Grp

Meeting Abstract. 2019

Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents

Park, Sophie; (...); Fenaux, Pierre

Letter. 10.1016/j.leukres.2020.106472. 2020

Outcome of older (=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

Kayser S; (...); Montesinos P

Article. 10.1038/s41375-020-0758-4. 2020

Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020)

Kayser, Sabine; (...); Montesinos, Pau

Correction. 10.1038/s41375-021-01358-3. 2021

Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Martinez-Cuadron, David; (...); Montesinos, Pau

Article. 10.3324/haematol.2022.282506. 2024

Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.

Caballero, Juan Carlos; (...); Diez Campelo, Maria

Article. 10.1177/20406207231218157. 2024

Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials

Ribera, JM; (...); PETHEMA Grp

Article. 10.1002/hon.2910. 2021

Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial

DiNardo, Courtney D.; (...); de Botton, Stephane

Meeting Abstract. 10.1182/blood-2021-147593. 2021

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Venditti, Adriano; (...); Pullarkat, Vinod

Meeting Abstract. 10.1182/blood-2023-182045. 2023

Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study

Perez-Lamas, Lucia; (...); Gutierrez, Valentin Garcia

Meeting Abstract. 10.1182/blood-2023-187412. 2023

Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib

Perez-Lamas, Lucia; (...); Garcia-Gutierrez, Valentin

Article. 10.1007/s00277-024-05906-6. 2024

Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.

Pleyer L; (...); Greil R

Article. 10.1016/S2352-3026(20)30374-4. 2021

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database

Shallis, RM; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-119755. 2018

Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients

Ibanez, Mariam; (...); Luna I

Article. 10.3390/diagnostics12040953. 2022

PAN-STAKEHOLDER CORE OUTCOME SET (COS) DEFINITION FOR HEMATOLOGICAL MALIGNANCIES IN THE FRAMEWORK OF THE EU PROJECT, HARMONY: THE HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINE OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY

Lang, K.; (...); Bullinger, L.

Meeting Abstract. 2023

Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects

Lang, Katharina M.; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2022-157549. 2022

Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance

Lang, Katharina M.; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2021-145002. 2021

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

Garcia-Robles, Ana; (...); Carrascosa, MA

Article. 10.3389/fped.2020.00372. 2020

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022

Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.

Sanz J; (...); Piñana JL

Article. 10.1016/j.bbmt.2019.08.020. 2020

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

Patient Reported Outcomes in Patients with Newly Diagnosed FLT3(mut+) acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone

Wang, Eunice S.; (...); Shah, Manasee V.

Meeting Abstract. 10.1182/blood-2021-144977. 2021

Patient-reported Outcomes in Adults With Newly Diagnosed Ph plus Acute Lymphoblastic Leukemia Treated With Ponatinib or Imatinib in Combination With Reduced-Intensity Chemotherapy: Results From the Phase III PhALLCON Study

Ashaye, Ajibade; (...); Guo, Shien

Meeting Abstract. 2024

PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines.

González-Romero E; (...); Vázquez-Manrique RP

Article. 10.3390/cancers15174263. 2023

Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study

Rodriguez-Medina, C; (...); Fernandez, PM

Article. 10.1016/j.leukres.2020.106352. 2020

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Stahl, M; (...); Zeidan, AM

Letter. 10.1080/10428194.2018.1468893. 2019

Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis

Hernández-Boluda JC; (...); Cervantes F

Letter. 10.1038/leu.2017.297. 2018

Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling

Orgueira, AM; (...); Lopez, JLB

Article. 10.3389/fonc.2021.657191. 2021

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Sargas, Claudia; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-166639. 2022

Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy

Margusino-Framiñán L; (...); Morillo-Verdugo R

Article. 10.7399/fh.11498. 2020

Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

Review. 10.2174/1389200218666171101124931. 2018

Pharmacologic evaluation of bispecific antibodies: A novel method to quantify their in vitro activity in hematologic samples.

Primo, D; (...); Ballesteros, J

Meeting Abstract. 2017

Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021

Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022

Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).

Walker, Alison R.; (...); William Burke, Patrick

Meeting Abstract. 2022

Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial.

Martinelli, Giovanni; (...); Montesinos, Pau

Meeting Abstract. 2022

Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy.

Wang, Eunice S.; (...); Tiu, V, Ramon

Article. 10.1182/blood.2021014586. 2022

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Wang, Eunice S.; (...); Tiu, Ramon V.

Meeting Abstract. 10.1182/blood-2021-145379. 2021

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Roboz, Gail J.; (...); Wei, Andrew H.

Letter. 10.1080/10428194.2021.2012667. 2022

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide

Horwitz, ME; (...); Sanz, G

Article. 10.1200/JCO.18.00053. 2019

Pilot evaluation of home delivery programme in haemophilia

Megias-Vericat, JE; (...); Poveda-Andres, JL

Article. 10.1111/jcpt.12718. 2018

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

Daver NG; (...); Kantarjian HM

Article. 10.1016/S1470-2045(23)00674-5. 2024

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2023-173413. 2023

PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS

Vericat, JEM; (...); Iorio, A

Meeting Abstract. 2020

PLZF-RAR(alpha), NPM1-RAR(alpha), and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review

Sobas, M; (...); Montesinos, P

Review. 10.3390/cancers12051313. 2020

Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results.

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Article. 10.1002/hem3.67. 2024

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA WITH PHILADELPHIA CHROMOSOME. RESULTS OF THE PONALFIL CLINICAL TRIAL WITH COMPLETE RECRUITMENT

Ribera, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2020

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIA CHROMOSOME. PRELIMINARY RESULTS OF THE PONALFIL CLINICAL TRIAL

Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2019

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIC CHROMOSOME (LAL PH plus ). RESULTS OF THE PONALFIL CLINICAL TRIAL WITH MEDIUM 2-YEAR FOLLOW-UP

Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2021

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Meeting Abstract. 10.1182/blood-2019-125558. 2019

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph plus ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Aldoss, Ibrahim; (...); Jabbour, Elias

Meeting Abstract. 10.1182/blood-2023-179537. 2023

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Jabbour, Elias; (...); Ribera, Jose-Maria

Article. 10.1001/jama.2024.4783. 2024

Ponatinib, Chemotherapy, and Transplant in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Article. 10.1182/bloodadvances.2022007764. 2022

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1007/s40261-019-00881-7. 2020

Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process

Valero, S; (...); Poveda, JL

Article. 10.1016/j.yrtph.2018.03.001. 2018

Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?

Sanz, Jaime, Montesinos, Pau, Sanz, Miguel A

Review. 10.1080/17474086.2020.1818559. 2020

Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments

Ballesteros, J; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-115849. 2018

Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model.

Hernández-Boluda JC; (...); Piñana JL

Article. 10.1016/j.bbmt.2020.07.022. 2020

PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS

Garcia, EG; (...); Ivorra, JAR

Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Shortt, Jake; (...); Wei, Andrew H.

Meeting Abstract. 10.1182/blood-2022-166937. 2022

Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Goetze, Katharina S. S.; (...); Platzbecker, Uwe

Meeting Abstract. 2024

Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.

García-Robles A; (...); Aguar-Carrascosa M

Letter. 10.1016/j.anpedi.2020.06.008. 2021

Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021

Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.

Cortes JE; (...); Wang ES

Review. 10.1186/s13045-020-00975-2. 2020

Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021

Prognosis and Survival of Acute Myeloid Leukemia: Experience of a Single Center in Colombia

Sossa, CL; (...); Jimenez, SI

Meeting Abstract. 10.1182/blood-2018-99-119927. 2018

Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Caballero, Teresa; (...); Perez-Simon, Jose A.

Meeting Abstract. 10.1182/blood-2021-151533. 2021

PROGNOSIS VALUE OF MINIMAL DETECTABLE DISEASE (MDD) BY 2(nd) GENERATION ALLOGENIC PRE-TRANSPLANTATION CYTOMETRY IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA

Velazquez Teresa, Caballero; (...); Jose Antonio, Perez Simon

Meeting Abstract. 2021

Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study.

Kanda J; (...); Gluckman E

Article. 10.1038/s41375-019-0534-5. 2020

Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).

Roboz, Gail J.; (...); Dohner, Hartmut

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7014. 2021

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts

Martin, I; (...); Sanz, G

Article. 10.1038/s41408-017-0016-9. 2017

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Dohner, Hartmut; (...); de Menezes, Daniel Lopes

Meeting Abstract. 10.1182/blood-2021-147465. 2021

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.

Dohner, Hartmut; (...); Lopes de Menezes D

Article. 10.1182/blood.2022016293. 2022

Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Uriel Suarez, Edwin; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-167365. 2022

Prognostic risk models for transplant decision-making in myelofibrosis

Hernandez-Boluda, JC; (...); Cervantes, F

Article. 10.1007/s00277-018-3240-x. 2018

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.

Castaño-Bonilla T; (...); Montesinos, P

Article. 10.1038/s41598-021-00050-x. 2021

Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.

Caballero-Velazquez, Teresa; (...); Perez-Simon, Jose A.

Article. 10.3390/cancers15051609. 2023

Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.

Muñoz-González JI; (...); Orfao A

Article. 10.1016/S2352-3026(20)30400-2. 2021

PROPOSED MOLECULAR CLASSIFICATION OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BASED ON SPLICING EVENTS

Liquori, A.; (...); Cervera Zamora, J.

Meeting Abstract. 2021

Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.

Sanz J; (...); Piñana JL

Article. 10.1016/j.bbmt.2019.10.014. 2020

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia

Pinana, JL; (...); Navarro, D

Article. 10.1016/j.jinf.2019.02.009. 2019

Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Marco-Ayala J; (...); Solves P

Review. 10.1038/s41409-020-01124-6. 2021

Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker

Perez-Alenda, S; (...); Querol, F

Letter. 10.1111/hae.13388. 2018

QuANTUM-First Trial: FLT3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS)

Levis, Mark J.; (...); Perl, Alexander E.

Meeting Abstract. 2023

Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Levis, Mark J.; (...); Perl, Alexander

Meeting Abstract. 10.1182/blood-2022-162739. 2022

Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction ( IND) and Consolidation CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3-ITD+ AML Patients (pts)

Perl, Alexander; (...); Levis, Mark J.

Meeting Abstract. 10.1182/blood-2023-186785. 2023

QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 2024

QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

Erba, Harry P.; (...); Montesinos, Pau

Meeting Abstract. 2024

QuANTUM-R: phase 3, randomised trial of Quizartinib in patients with FLT3-Internal tandem duplication (FLT3-ITD)-positive relapsed/refractory (R/R) acute myeloid meukaemia (AML)

Radsak, M. P.; (...); Levis, M. J.

Meeting Abstract. 2019

Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 10.1093/annonc/mdz374.003. 2019

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.

Erba, Harry P.; (...); Schlenk, Richard F.

Article. 10.1016/S0140-6736(23)00464-6. 2023

Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML

Schlenk, R.; (...); Erba, H.

Meeting Abstract. 2022

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Cortes, JE; (...); Levis, MJ

Article. 10.1016/S1470-2045(19)30150-0. 2019

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Cortes, JE; (...); Heuser, M

Article. 10.1038/s41375-018-0312-9. 2019

Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/ Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis

Garcia-Manero, Guillermo; (...); Yacoub, Abdulraheem

Meeting Abstract. 2023

RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

Garcia-Manero, G.; (...); Yacoub, A.

Meeting Abstract. 10.1016/j.leukres.2023.107270. 2023

Rapid and Robust CD4+and CD8+T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

de Koning, Coco; (...); Boelens, Jaap-Jan

Meeting Abstract. 2019

Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project.

Serrano-Gonzalo, Irene; (...); Giraldo, Pilar

Article. 10.1186/s13023-023-02939-4. 2023

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA plus )

Falantes, J; (...); European ALMA?+?Investigators

Article. 10.1080/10428194.2017.1365854. 2018

Real life outcomes of patients aged =75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.

Salamero O; (...); PETHEMA and PALG Groups

Article. 10.1080/10428194.2019.1607327. 2019

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

Luna, A.; (...); Garcia-Gutierrez, V

Article. 10.1007/s00277-022-04932-6. 2022

Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Saiz-Rodriguez, M; (...); Pethema Grp

Meeting Abstract. 2021

REAL-LIFE EVIDENCE OF VENETOCLAX TREATMENT IN PATIENTS WITH ACUTE REPLAPSE OR REFRACTORY LEUKEMIA MYELOID

Jorge, Labrador; (...); Pau, Montesinos

Meeting Abstract. 2021

Real-world experience with CPX-351 in high-risk acute myeloid leukemia.

Lemoli, Roberto M., Montesinos, Pau, Jain, Akriti

Article. 10.1016/j.critrevonc.2023.103984. 2023

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged = 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Requena, Gaspar Aspas; (...); Matinez-Cuadron, David

Meeting Abstract. 10.1182/blood-2023-190128. 2023

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Sauta, Elisabetta; (...); Della Porta, Matteo G.

Meeting Abstract. 10.1182/blood-2022-163634. 2022

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

Sauta, Elisabetta; (...); Della Porta, Matteo Giovanni

Article. 10.1200/JCO.22.01784. 2023

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.

Hernandez-Sanchez, Alberto; (...); Bullinger, Lars

Article. 10.1038/s41375-024-02333-4. 2024

Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Hernandez Sanchez, Alberto; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2022-167480. 2022

Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2.

Montesinos, Pau; (...); Heuser, Michael

Article. 10.3390/cancers16101824. 2024

REMOVAL OF GERMINAL LINE MUTATIONS IN PATIENTS WITH MDS AND AML: WHO SHOULD BE PERFORMED?

Santiago, Marta; (...); Cervera, Jose

Meeting Abstract. 2020

RESCUE TREATMENT WITH DECITABINE AFTER PROGRESSION TO AZACITIDINE IN AML

De la Fuente, A; (...); Montesinos, P

Meeting Abstract. 2018

Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria*

Triguero, A.; (...); Sanz, G.

Article. 10.1016/j.leukres.2022.106836. 2022

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Roboz, Gail J.; (...); Dohner, Hartmut

Meeting Abstract. 10.1182/blood-2021-147769. 2021

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Kantarjian, Hagop M.; (...); Chiao, Judy H.

Article. 10.1002/cncr.33828. 2021

Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.

Torrent, Anna; (...); Ribera, Josep-Maria

Article. 10.1111/ejh.14031. 2023

RESULTS OF THE TREATMENT OF LYMPHOBLASTIC LYMPHOMA WITH PROTOCOLS OF LYMPHOBLASTIC ACUTE LEUKEMIA OF PETHEMA GROUP

Sagues, M.; (...); Ribera, J. M.

Meeting Abstract. 2019

Results of two protocols for platelet transfusion in patients undergoing abo incompatible hematopoietic stem cell transplantation

Solves, P; (...); Sanz, G

Letter. 10.1016/j.transci.2019.02.002. 2019

Revisiting Co-existing Chromosomal Abnormalities in NPM1-mutated AML in Light of the Revised ELN 2022 classification.

Angenendt, Linus; (...); Schliemann, Christoph

Article. 10.1182/blood.2022018582. 2022

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Ribera, Josep-Maria; (...); Sancho, Juan-Manuel

Meeting Abstract. 10.1182/blood-2019-125683. 2019

RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib

Such, E; (...); Cervera, J

Article. 10.1159/000497348. 2019

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Ribera, Jordi; (...); Ribera, Josep-Maria

Meeting Abstract. 10.1182/blood-2023-186265. 2023

Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia.

Review. 10.3389/fonc.2021.614215. 2021

Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Paiva, B; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-113299. 2018

Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.

Pinto-Merino, Alvaro; (...); Saiz-Rodriguez, Miriam

Article. 10.3390/pharmaceutics14030559. 2022

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Zeidan, Amer M.; (...); Garcia-Manero, Guillermo

Meeting Abstract. 10.1182/blood-2021-145626. 2021

SAFETY AND EFFECTIVENESS OF ASCIMINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER FAILURE OF VARIOUS TYROSINE KINASE INHIBITORS

Luna, de Abia Alejandro; (...); Garcia, Gutierrez Valentin

Meeting Abstract. 2020

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2021-146503. 2021

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.

Garcia-Gutiérrez V; (...); Hernández-Boluda JC

Letter. 10.1038/s41408-021-00420-8. 2021

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.

Montesinos P; (...); Wei AH

Article. 10.1038/s41375-020-0773-5. 2020

Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review

Review. 10.1007/s00277-018-3304-y. 2018

Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups

Vives, Susana; (...); PETHEMA Grp

Article. 10.3390/cancers16234028. 2024

Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.

Sole, A; (...); Peman, J

Article. 10.1111/ajt.14580. 2018

Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.

Moles-Poveda, P; (...); Botella-Estrada, R

Article. 10.1016/j.ad.2017.11.003. 2018

SCREENING FOR POTENTIAL THERAPEUTIC OPPORTUNITIES FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH IKZF1 DELETIONS

Ribera, Jordi; (...); Ribera, Josep Maria

Meeting Abstract. 2020

Secondary Acute Myeloid Leukemia from a Previous Chronic Myeloproliferative Neoplasm: A Study of Grelam-Chile Concerning Chilean Patients on Behalf of AML Pethema Registry

Espinoza, Marcela; (...); Martinez-Cuadron, David

Meeting Abstract. 10.1182/blood-2023-185288. 2023

SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11565. 2020

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Paoli, Alessandro; (...); Pellacani, Andrea

Meeting Abstract. 10.1182/blood-2021-150277. 2021

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.

Cortes JE; (...); Heuser M

Review. 10.1080/10428194.2020.1817445. 2020

Sex differences in aortic prognosis in Marfan patients, a retrospective longitudinal study from the REPAG registry

Tura, G. Teixido; (...); Cabrera, F.

Meeting Abstract. 10.1093/eurheartj/ehae666.2264. 2024

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Torrent, Anna; (...); Ribera, Josep-Maria

Meeting Abstract. 10.1182/blood-2024-207954. 2024

SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.

Risueno, Alberto; (...); Hasan, Maroof

Article. 10.1016/j.leukres.2024.107497. 2024

Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Palomo L; (...); Such E

Article. 10.1111/bjh.16175. 2020

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Zeidan, AM; (...); Mascarenhas, J

Review. 10.1016/S2352-3026(20)30205-2. 2020

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.

Shallis RM; (...); Zeidan AM

Article. 10.1016/S2352-3026(23)00159-X. 2023

STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)+azacitidine in higher risk MDS and CMML-2.

Zeidan AM; (...); Santini V

Article. 10.2217/fon-2022-1237. 2023

STUDY OF MUTATIONAL PROFILE AND CORRELATION OF RESPONSE TO EX VIVO PHARMACOLOGICAL TEST, IN THE DIAGNOSTIC OF THE AML

de la Fuente, EO; (...); Diaz, RA

Meeting Abstract. 2018

STUDY OF PRE-EXISTING MUTATIONS IN HEMATOPOYETIC CELLS OF THE BONE MEDULA IN PATIENTS WITH MYELOID NEOPLASIAS RELATED TO THERAPY

Ibanez, M; (...); Sanz, G

Meeting Abstract. 2017

STUDY OF THE MECHANISMS OF THROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS

Agula, S.; (...); Ferrer-Marin, F.

Meeting Abstract. 2021

STUDY OF TRANSCRIPTIONAL DIFFERENCES BETWEEN THE IDH2 R140 AND R172 MUTATIONS BY MEANS OF MODELING IN THE ORGANISM CAENORHABDITIS ELEGANS

Gonzalez, Romero Elisa; (...); Cervera, Jose Vicente

Meeting Abstract. 2020

Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes

Mosquera Orgueira, Adrian; (...); Valcarcel, David

Meeting Abstract. 10.1182/blood-2022-159429. 2022

Survival of Patients with Acute Myeloid Leukemia According to Age in a University Hospital in Colombia

Melo, CLS; (...); Montesinos, P

Meeting Abstract. 2021

Survival of Patients with Acute Myeloid Leukemia, Taken to Hematopoietic Stem Cell Transplantation: Experience of A Center in Colombia

Melo, CLS; (...); Ortiz, MF

Meeting Abstract. 2021

Survival of Patients with Secondary Acute Myeloid Leukemia in a University Hospital in Colombia

Ortiz, MF; (...); Sossa, C

Meeting Abstract. 2021

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Cortes, JE; (...); Heuser, M

Article. 10.1186/s13045-020-00929-8. 2020

Survival Outcomes for Patients (pts) in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine (Oral-AZA) or Placebo (PBO)

Pfeilstoecker, M.; (...); Doehner, H.

Meeting Abstract. 2023

Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo

Ravandi, Farhad; (...); Doehner, Hartmut

Meeting Abstract. 10.1182/blood-2022-159045. 2022

Survival outcomes from the QUAZAR AML-001 trial with oral azacitidine (Oral-AZA) for patients with acute myeloid leukemia (AML) in remission by disease subtype, cytogenetic risk, and NPM1 mutation status at diagnosis (Dx)

Pfeilstoecker, Michael; (...); Menezes, Daniel

Meeting Abstract. 2022

Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.

Ravandi, Farhad; (...); Roboz, Gail J

Article. 10.1111/bjh.19202. 2023

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase 3 QUAZAR AML-001 trial.

Wei AH; (...); Ravandi F

Article. 10.3324/haematol.2022.282296. 2023

SUSPENSION OF TREATMENT WITH BCR-ABL INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE

Galan, IP; (...); Boluda, JCH

Meeting Abstract. 2017

Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Review. 10.3390/pharmaceutics14040878. 2022

t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group

Ribera, J; (...); Ribera, JM

Meeting Abstract. 2021

Table 1. Clinical-biological and molecular characteristics of CML patients in each group evaluated

Agula, S.; (...); Ferrer-Marin, F.

Meeting Abstract. 2021

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.

Martín-Sánchez E; (...); Zabaleta A

Article. 10.1182/bloodadvances.2024013212. 2024

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey

Pigneux, A; (...); Bruggemann, M

Article. 10.1186/s12885-018-5002-5. 2018

The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022

The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation.

Piñana J; (...); Sanz J

Article. 10.1016/j.jinf.2019.12.022. 2020

THE COMBINATION OF GENOMIC ANALYSIS AND MINIMAL RESIDUAL DISEASE IMPROVES THE STRATIFICATION OF ADULT PATIENTS WITH TYPE T-LYMPHOBLASTIC LEUKEMIA (LAL-T) TREATED ACCORDING TO THE PETHEMA PROTOCOLS

Gonzalez Gil, C.; (...); Genesca Ferrer, E.

Meeting Abstract. 2021

The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022

The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey.

Piñana JL; (...); Navarro D

Article. 10.1038/s41409-019-0698-7. 2020

The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe

Platzbecker, Uwe; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2021-145099. 2021

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Mosquera Orgueira, Adrian; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-180482. 2023

The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.

Kanda, Junya; (...); Gluckman, Eliane

Article. 10.1038/s41409-021-01479-4. 2022

The Impact of GVHD on Outcomes After Adult Single Cord Blood Transplantation In European And Japanese Populations: The EUROCORD/ALWP EBMT And JSHCT/JDCHCT Collaborative Study

Kanda, J; (...); Gluckman, E

Meeting Abstract. 2021

The modular network structure of the mutational landscape of Acute Myeloid Leukemia

Ibanez, M; (...); Cervera, J

Article. 10.1371/journal.pone.0202926. 2018

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

Ayala, R; (...); Montesinos, P

Article. 10.3390/cancers13102458. 2021

The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients

Ribera, J; (...); Ribera, JM

Article. 10.1111/bjh.15887. 2019

The QUAZAR AML-001 maintenance trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of oral CC-486 in patients with Acute Myeloid Leukemia (AML) in first remission

Dohner, H; (...); Roboz, GJ

Meeting Abstract. 2020

The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.

Villar, Sara; (...); Montesinos, Pau

Article. 10.3389/fonc.2022.1054458. 2022

The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Badia, Xavier; (...); Valles, Joan-Antoni

Article. 10.1186/s13023-024-03324-5. 2024

The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus

Torrent-Farnell, J; (...); Lizan, L

Article. 10.1016/j.healthpol.2018.03.002. 2018

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Kuendgen A; (...); Sanz G

Article. 10.1038/s41375-020-0917-7. 2020

Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors

Aguila, Sonia; (...); Ferrer Marin, Francisca

Meeting Abstract. 10.1182/blood-2022-163070. 2022

Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain

Boluda, B; (...); Montesinos, P

Article. 10.1007/s41669-018-0098-8. 2019

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.

Jonas, Brian A.; (...); Ofran, Yishai

Article. 10.1002/ajh.26600. 2022

Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.

Marques MR; (...); Mangas-Sanjuan V

Article. 10.1111/apa.14944. 2020

Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.

Mora E; (...); Sanz J

Article. 10.1038/s41409-024-02298-z. 2024

Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).

Efficace, Fabio; (...); Zeidan, Amer M

Article. 10.1002/hem3.69. 2024

Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy

Del Rio-Bermudez, C; (...); Poveda, JL

Editorial Material. 10.1186/s40545-020-00276-6. 2020

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.

Perez-Lamas, Lucia; (...); Garcia-Gutierrez, Valentin

Article. 10.3390/cancers15041045. 2023

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Perez-Lamas, Lucia; (...); Garcia Gutierrez, Valentin

Meeting Abstract. 10.1182/blood-2022-167453. 2022

Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024

TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion

Montoro Gomez, Maria Julia; (...); Valcarcel, David

Meeting Abstract. 10.1182/blood-2022-165257. 2022

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Patricia Simoes, Catia; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2022-163159. 2022

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.

Simoes, Catia; (...); Montesinos, Pau

Letter. 10.1111/bjh.18815. 2023

TRANSCRIPTIONAL CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA AT DIAGNOSIS IN THE ELDERLY PATIENT WITH IDENTIFICATION OF NEW PROGNOSTIC GROUPS

Sara, Villar; (...); Pau, Montesinos

Meeting Abstract. 2021

TRANSCRIPTOMICAL ANALYSIS AND MODELING IN C.ELEGANS OF THE IDH2 R140 R172 MUTATION

Gonzalez-Romero, E.; (...); Cervera-Zamora, J., V

Meeting Abstract. 2019

Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.

Solves, Pilar; (...); Sanz, Jaime

Article. 10.3390/jcm12103467. 2023

Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study.

Crisà E; (...); Santini V

Article. 10.1038/s41375-024-02360-1. 2024

Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre.

Solves P; (...); Carpio N

Article. 10.1016/j.transci.2019.09.011. 2020

Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force.

Klepin HD; (...); Cordoba R

Review. 10.1016/j.jgo.2020.03.019. 2020

Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy

Ribera, JM; (...); Spanish Soc Hematology

Article. 10.1016/j.clml.2020.03.011. 2020

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Martinez-Cuadron, David; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-189800. 2023

Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.

Lloret-Madrid, Pilar; (...); Montesinos, Pau

Article. 10.1002/cncr.35696. 2025

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1182/bloodadvances.2021005335. 2022

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

Diez-Campelo, Maria; (...); Valcarcel, David

Meeting Abstract. 10.1182/blood-2021-146019. 2021

Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?